TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7484887
Drug: Perindopril (4‐8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perindopril (4‐8 mg orally) with possible addition of isradipine (5‐10 mg orally) and hydralazine if necessary
Study: 1791799
Drug: Ambroxol (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol (intravenous infusion)
Study: 1791799
Drug: Tokio‐Akita (TA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tokio‐Akita (TA) surfactant (endotracheal administration)
Study: 1791799
Drug: Placebo (endotracheal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (endotracheal administration)
Study: 31398441
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg caffeine (placebo)
Study: 18984662
Drug: 240 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg/d oral iron alone
Study: 18984662
Drug: 240 mg/d
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg/d oral iron plus 75 microg/d levothyroxine
Study: 16893507
Drug: Insulin drip
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin drip
Study: 8313865
Drug: Clarithromycin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin (500 mg bid)
Study: 8313865
Drug: Amoxicillin/clavulanate (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin/clavulanate (500 mg tid)
Study: 3091629
Drug: Continuous GHRH
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous GHRH infusion (0.15 microgram/kg X h for 5 h, followed by 0.75 microgram/kg X h for 5 h)
Study: 3091629
Drug: Single GHRH
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single GHRH bolus dose (1 microgram/kg, iv) after continuous GHRH infusion
Study: 29557398
Drug: Augmentation procedures
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation procedures
Study: 21891773
Drug: Extra high-volume
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extra high-volume hemofiltration (EHVHF) at 85 mL/kg/h
Study: 21891773
Drug: High-volume hemofiltration
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume hemofiltration (HVHF) at 50 mL/kg/h
Study: 20358276
Drug: GES-scoring plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: GES-scoring plus sHLA-G expression (Group B)
Study: 17974605
Drug: Intra-arterial contrast
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial contrast injection (IACTA)
Study: 17974605
Drug: Conventional CT
Normalized name: CT-179
DrugBank: CT-179 (DB17114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional CT angiography with intravenous contrast injection (IVCTA)
Study: 10612135
Drug: Arthroscopically assisted
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arthroscopically assisted bone‐tendon‐bone A.C.L. reconstruction
Study: 10612135
Drug: Open procedure
Normalized name: BOTTLE OPENER
Approvals — FDA: no, EMA: no, PMDA: no
Description: Open procedure A.C.L. reconstruction
Study: 2024559
Drug: 0.5% bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% bupivacaine with epinephrine (5 micrograms.ml‐1)
Study: 23754514
Drug: Darexaban-MR 120
Normalized name: verapamil hydrochloride Extended Release Oral Tablet [Ethimil MR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Darexaban-MR 120 mg qd + digoxin 0.25 mg qd
Study: 23754514
Drug: Placebo +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo + digoxin 0.25 mg qd
Study: 19574992
Drug: Midazolam 0.2
Normalized name: midazolam 0.2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 0.2 mg/kg premedication
Study: 10743479
Drug: Placebo tablet
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet each day
Study: 10743479
Drug: 500 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 micrograms folic acid and placebo tablets on alternate days
Study: 7723371
Drug: LPD (epirubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPD (epirubicin 15-40 mg/m2 and Lipiodol 0.02-0.25 ml/kg)
Study: 2386364
Drug: Intravenous cefetamet
Normalized name: cefetamet
DrugBank: Cefetamet (DB13504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous cefetamet
Study: 2386364
Drug: Oral cefetamet
Normalized name: cefetamet
DrugBank: Cefetamet (DB13504)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral cefetamet pivoxil
Study: 7150459
Drug: Cimetidine (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (300 mg every 6 h for 4 days)
Study: 24947926
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus vismodegib (VIS)
Study: 19717243
Drug: Behavioral Family
Approvals — FDA: no, EMA: no, PMDA: no
Description: Behavioral Family Counseling (BFC) plus Individual-Based Treatment (IBT)
Study: 19717243
Drug: Individual-Based Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual-Based Treatment (IBT) alone
Study: 14633758
Drug: 30% oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30% oxygen with droperidol 0.625 mg
Study: 8682157
Drug: Calculated activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calculated activity to deliver a thyroid dose of 100 Gy
Study: 6763202
Drug: Aspirin 650
Normalized name: aspirin 650 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 650 mg + Codeine 60 mg
Study: 6763202
Drug: Ibuprofen 400
Normalized name: ibuprofen 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 400 mg + Codeine 60 mg
Study: 28058962
Drug: Lidocaine (LI)
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine (LI) injection
Study: 23475164
Drug: Nitrate-rich concentrated
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-rich concentrated beetroot juice (BR; 2 × 250 mL·d, ∼8.2 mmol·d nitrate)
Study: 23475164
Drug: Nitrate-depleted BR
Normalized name: Respa-BR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitrate-depleted BR placebo (PL; 2 × 250 mL·d, ∼0.006 mmol·d nitrate)
Study: 19407730
Drug: Desvenlafaxine (50-400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine (50-400 mg/day)
Study: 19407730
Drug: Desvenlafaxine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Desvenlafaxine (400 mg/day)
Study: 17217572
Drug: 1000 mg
Normalized name: bran 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1000 mg Ca/d
Study: 17217572
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg Ca/d
Study: 15060225
Drug: Medication algorithm-medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication algorithm-medication alone (MedMgt)
Study: 15060225
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (Comb)
Study: 15060225
Drug: Community comparison
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community comparison (CC)
Study: 15060225
Drug: Med/NoMed (stopping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Med/NoMed (stopping medication)
Study: 15060225
Drug: Med/Med (consistent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Med/Med (consistent medication use)
Study: 15060225
Drug: NoMed/Med (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: NoMed/Med (starting medication)
Study: 15060225
Drug: NoMed/NoMed (never
Approvals — FDA: no, EMA: no, PMDA: no
Description: NoMed/NoMed (never reported medication use)
Study: 9676863
Drug: Intravenous clonidine
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous clonidine 2 microg kg(‐1)
Study: 7848364
Drug: Cotrimoxazole preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cotrimoxazole preparations and placebo
Study: 7848364
Drug: Multivitamin preparations
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin preparations and placebo
Study: 3261612
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (active treatment)
Study: 30980569
Drug: Evidence-based medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evidence-based medicine practices in obstetrics
Study: 28686675
Drug: Cetirizine 10
Normalized name: cetirizine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cetirizine 10 mg added after each IFNβ injection for 4 weeks
Study: 28686675
Drug: Placebo added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo added to the standard treatment for FLS for 4 weeks
Study: 23701059
Drug: Intraparenchymal blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraparenchymal blood patch
Study: 23701059
Drug: Intraparenchymal blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraparenchymal blood patch with 19-gauge needle
Study: 23701059
Drug: Intraparenchymal blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraparenchymal blood patch with 17-gauge needle
Study: 21591944
Drug: Selenium (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium (100 μg twice daily)
Study: 21591944
Drug: Pentoxifylline (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (600 mg twice daily)
Study: 19246990
Drug: HCV Core
Normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCV Core ISCOMATRIX vaccine (5, 20, or 50 microg HCV Core protein with 120 mug ISCOMATRIX adjuvant)
Study: 7886411
Drug: Lignocaine 400
Normalized name: lidocaine hydrochloride Injectable Solution [Sure-Amp Lignocaine hydrochloride]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lignocaine 400 mg (40 ml of a 1% solution) instilled for 1 hour in Group A patients (n = 9)
Study: 29290184
Drug: Intense Pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intense Pulse Light Therapy (IPL) and Triple Combination Cream (TCC)
Study: 29290184
Drug: Intense Pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intense Pulse Light Therapy (IPL)
Study: 18235121
Drug: Imatinib 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 600 mg/d
Study: 16284710
Drug: Microtip and
Normalized name: Babesia microti preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microtip and water pressure transducer combination
Study: 11306153
Drug: Four-drug combination
Normalized name: Four-Way
Approvals — FDA: no, EMA: no, PMDA: no
Description: Four-drug combination with protease inhibitor (PI) and non-nucleoside reverse transcriptase inhibitor (NNRTI) plus nucleoside analogue (NRTI) drugs
Study: 11306153
Drug: Three-drug combinations
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three-drug combinations (PI followed by NNRTI or NNRTI followed by PI)
Study: 9736326
Drug: Bromocriptine (BRC)
DrugBank: Bromocriptine (DB01200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromocriptine (BRC) 2.5 mg daily
Study: 2741861
Drug: Furosemide (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (1 mg/kg IV every 24 hours)
Study: 2741861
Drug: Ethacrynic acid
Normalized name: Ethacrynic Acid
DrugBank: Etacrynic acid (DB00903)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ethacrynic acid (1 mg/kg IV every 24 hours)
Study: 2741861
Drug: Furosemide and
Normalized name: furosemide and potassium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide and ethacrynic acid (alternating doses)
Study: 22008766
Drug: No isoniazid
Normalized name: Isoniazid
DrugBank: Isoniazid (DB00951)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: No isoniazid preventive therapy (non-completers)
Study: 30795794
Drug: Alpha power-maximisation
Normalized name: One-Alpha
DrugBank: Alfacalcidol (DB01436)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alpha power-maximisation anaesthesia titration strategy during maintenance phase of anaesthesia
Study: 30795794
Drug: Early cessation
Normalized name: bupropion
DrugBank: Bupropion (DB01156)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early cessation of volatile anaesthesia and emergence from an intravenous infusion of propofol during emergence phase of anaesthesia
Study: 29429537
Drug: Beverage containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beverage containing 20 g of soluble fiber dextrin (SFD)
Study: 29429537
Drug: Beverage containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beverage containing 0 g of soluble fiber dextrin (control)
Study: 29429537
Drug: Beverage containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beverage containing 10 g of soluble fiber dextrin (SFD)
Study: 24072776
Drug: MASS criteria
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MASS criteria evaluation after therapy
Study: 24072776
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of baseline serum LDH levels and MASS criteria evaluation
Study: 22855276
Drug: N(G)-nitro-l-arginine methyl
Normalized name: methyl L-arginine
Approvals — FDA: no, EMA: no, PMDA: no
Description: N(G)-nitro-l-arginine methyl ester (l-NMMA)
Study: 20199883
Drug: Circulating lipids
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Circulating lipids measurement, oral glucose tolerance test (OGTT), and hormonal screening including GH secretory capacity (GHRH/arginine test).
Study: 20199883
Drug: Assessment of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assessment of visceral to subcutaneous abdominal fat ratio.
Study: 20199883
Drug: Correlation analysis
Normalized name: Chemicals and reagents for analysis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Correlation analysis of visceral abdominal fat fraction with subcutaneous fat, BMI, and peak GH-response.
Study: 20199883
Drug: Sex-steroid replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sex-steroid replacement therapy.
Study: 3291526
Drug: dDAVP treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: dDAVP treatment
Study: 11890429
Drug: Real acupuncture
Normalized name: REAL FOODS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Real acupuncture treatment with needles
Study: 8847017
Drug: Locoregional immunostimulation
Normalized name: IMMUNOSTIMULANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locoregional immunostimulation and locoregional chemotherapy (Proleukin and Imukin infusion for 10 days, followed by locoregional chemotherapy 15 days later)
Study: 1904189
Drug: Invasive versus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Invasive versus conservative treatment strategies
Study: 1904189
Drug: Early versus
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early versus delayed beta-blocker therapy
Study: 7264274
Drug: Oral diethylcarbamazine
Normalized name: diethylcarbamazine
DrugBank: Diethylcarbamazine (DB00711)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral diethylcarbamazine (DEC)
Study: 28073858
Drug: Fractional-dose inactivated
Normalized name: Poliovirus, inactivated, fractional-dose (fIPV)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional-dose inactivated poliovirus vaccine (fIPV) administered intradermally on days 0 and 28
Study: 28073858
Drug: Full-dose inactivated
Normalized name: Rho(D) immune globulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose inactivated poliovirus vaccine (IPV) administered intramuscularly on days 0 and 28
Study: 24975432
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine as first-line treatment
Study: 24975432
Drug: Oral oxycodone
Normalized name: oxycodone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxycodone as first-line treatment
Study: 24975432
Drug: Oral morphine
Normalized name: morphine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral morphine as second-line treatment after switching
Study: 24975432
Drug: Oral oxycodone
Normalized name: oxycodone Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral oxycodone as second-line treatment after switching
Study: 24975432
Drug: Adverse reactions
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse reactions to oral morphine
Study: 24975432
Drug: Adverse reactions
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse reactions to oral oxycodone
Study: 23171815
Drug: Exercise augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise augmentation with 16 kilocalories per kilogram of body weight per week (KKW) for 12 weeks
Study: 23171815
Drug: Exercise augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise augmentation with 4 KKW for 12 weeks
Study: 23171815
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitor (SSRI) augmentation
Study: 19519257
Drug: Methylphenidate transdermal
Normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate transdermal system (MTS) applied to the hip area
Study: 19519257
Drug: Methylphenidate transdermal
Normalized name: methylphenidate Transdermal System
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate transdermal system (MTS) applied to the scapular area
Study: 18269868
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine plus glimepiride 3 mg
Study: 18269868
Drug: Premixed 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Premixed 30 R insulin (70/30) twice‐daily plus glimepiride 3 mg
Study: 15287454
Drug: Cerebral perfusion
Normalized name: Sus scrofa cerebral cortex preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebral perfusion pressure (CPP) targeted therapy
Study: 9439559
Drug: Healthy-living advice
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy-living advice and sulfonylurea therapy
Study: 31448832
Drug: 1.2% SMV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2% SMV gel and covering the defect with occlusive membrane (OM)
Study: 31448832
Drug: 1.2% SMV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.2% SMV gel and covering the defect with perforated barrier membranes (PBM)
Study: 31448832
Drug: 24% EDTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24% EDTA root surface etching, 1.2% SMV gel, and defect coverage with occlusive membrane (eOM)
Study: 31448832
Drug: 24% EDTA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 24% EDTA root surface etching, 1.2% SMV gel, and defect coverage with perforated barrier membranes (ePBM)
Study: 25404537
Drug: 5-HT3 receptor
Normalized name: 5-HT3 receptor antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HT3 receptor antagonist
Study: 23422652
Drug: Daily G-CSF
Normalized name: G-CSF
DrugBank: Lenograstim (DB13144)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily G-CSF administration
Study: 23422652
Drug: Every other
Normalized name: Ether
DrugBank: Diethyl ether (DB13598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Every other day G-CSF administration
Study: 17029276
Drug: Low-dose interferon-alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Low-dose interferon-alpha-2b (IFN1) at a dose of 0.5 million units (MU) given subcutaneously twice daily
Study: 17029276
Drug: Intermediate-dose interferon-alpha-2b
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intermediate-dose interferon-alpha-2b (IFN5) at a dose of 5 MU given subcutaneously daily
Study: 14990561
Drug: High-dose phase
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose phase (HP) after 4 months of OC use at 45% Vo(2 peak)
Study: 14990561
Drug: High-dose phase
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose phase (HP) after 4 months of OC use at 65% Vo(2 peak)
Study: 8504632
Drug: L-Dihydroxyphenylalanine infusion
Normalized name: L-3,4-dihydroxyphenylalanine
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: L-Dihydroxyphenylalanine infusion (0.33 micrograms min‐1 kg‐1)
Study: 3308617
Drug: Vidarabine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vidarabine (15 mg/kg/day for 7 days then 7.5 mg/kg/day for 14 days)
Study: 28424081
Drug: Increased vegetable
Normalized name: Hydrogenated Vegetable Oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased vegetable portion sizes (150 g instead of 75 g) and decreased meat portion sizes (average reduction of 12.5%) during the intervention period.
Study: 29895556
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine 100 units/mL (Gla‐100)
Study: 22938664
Drug: Insulin glargine
Normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin glargine and regular insulin injection (experiment group)
Study: 22938664
Drug: Subcutaneous regular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous regular insulin injection (control group)
Study: 19283567
Drug: Pharmacologic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic treatment (psychoactive medication)
Study: 19283567
Drug: Non-pharmacologic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-pharmacologic treatment approaches
Study: 17602983
Drug: Beta-blocker therapy
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beta-blocker therapy (general)
Study: 7846537
Drug: Doxorubicin (45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxorubicin (45 mg/m2)
Study: 7846537
Drug: Epirubicin (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (60 mg/m2)
Study: 7846537
Drug: Epirubicin (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin (90 mg/m2)
Study: 2695500
Drug: 3 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 Gy daily on 20 consecutive days (total dose 60 Gy, TDF factor 123)
Study: 2695500
Drug: 4 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 Gy 3 times per week until 12 irradiations (total dose 48 Gy, TDF factor 103)
Study: 28727591
Drug: EMLA (daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: EMLA (daily use for 4 weeks as a primary dressing)
Study: 11778111
Drug: Ropivacaine 0.5%
Normalized name: ROPivacaine 0.5% injectable solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ropivacaine 0.5% combined with sufentanil 30 mcg (group S)